Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • BridgeBio Pharma's Depreciation & Amortization (CF) fell 910.27% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 1473.07%. This contributed to the annual value of $6.1 million for FY2024, which is 645.21% down from last year.
  • Per BridgeBio Pharma's latest filing, its Depreciation & Amortization (CF) stood at $1.4 million for Q3 2025, which was down 910.27% from $1.3 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Depreciation & Amortization (CF) high stood at $3.5 million for Q2 2021, and its period low was $265000.0 during Q3 2021.
  • Over the past 5 years, BridgeBio Pharma's median Depreciation & Amortization (CF) value was $1.6 million (recorded in 2022), while the average stood at $1.5 million.
  • The largest annual percentage gain for BridgeBio Pharma's Depreciation & Amortization (CF) in the last 5 years was 52075.47% (2022), contrasted with its biggest fall of 5461.85% (2022).
  • Over the past 5 years, BridgeBio Pharma's Depreciation & Amortization (CF) (Quarter) stood at $1.5 million in 2021, then rose by 8.78% to $1.7 million in 2022, then fell by 4.52% to $1.6 million in 2023, then decreased by 13.75% to $1.4 million in 2024, then increased by 2.27% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.